Purexa™ OdT mRNA Affinity Membrane Product Update
Purilogics is currently developing a novel and first-in-market high-capacity, -selectivity, and -throughput affinity membrane for the purification of mRNA. The research, development, and testing for this product, Purexa™ OdT, is supported by a grant awarded to Purilogics from the Small Business Innovation Research (SBIR) Direct to Phase II program of the National Institutes of Health (NIH). Read our previous post to learn more about this award and our goals for the Purexa™ OdT mRNA affinity membrane. In this post, we aim to provide a performance update on Purexa™ OdT and highlight how the product currently performs against leading commercially available mRNA affinity resins.
Dynamic Binding Capacity (DBC) vs. Flowrate
Figure 1: Purexa™ OdT DBC vs. Flowrate
Figure 2: Commercial Affinity Resin DBC vs. Flowrate
In Figure 1, we see that the Dynamic Binding Capacities (DBCs) of the Purexa™ OdT membranes remain very high at higher flowrates. Comparatively, Figure 2 illustrates that commercial affinity resins start out with approximately half the binding capacity at an extremely low flowrate of 0.25 CV/min, and decreases by nearly 50% when this flowrate is increased to 1 CV/min. For these comparisons, we used GFP 800 nts mRNA.
DBC vs Flowrate at Varying mRNA Sizes
Figure 3: Purexa™ OdT Relative DBC of 800 and 4000 nts vs. Flowrate
Figure 4: Commercial Affinity Resin Relative DBC of 800 and 4000 nts vs. Flowrate
Figures 3 and 4 again illustrate the high DBC at high flowrates for Purilogics products compared to commercial affinity resins. These figures also show the difference in DBC at different flow rates between different mRNA sizes of 800 and 4000 nts. For commercial resins, the DBC is significantly affected and decreases dramatically for 4000 nts. However, Purilogics Purexa™ OdT membranes maintain relatively consistent DBCs between 800 and 4000 nts at all flowrates. Furthermore, for commercial resins, we see the DBC decrease by approximately 40% for both mRNA when flowrate is increased from 0.25 CV/min to 1 CV/min.
mRNA Recovery vs. Flowrate
Figure 5: Purexa™ OdT Percent Recovery vs. Flowrate
Figure 6: Commercial Affinity Resin Percent Recovery vs. Flowrate
Figures 5 and 6 compare mRNA recovery with flowrate. Figure 5 shows that despite high flowrates, up to 80 MV per minute, the Purexa™ OdT membranes retain nearly the same recovery as the commercial affinity resins. For Figures 5 and 6, we also observed the recovery for both 800 nts and 4000 nts mRNA.
Summary
Our Purexa™ OdT membrane products maintain high dynamic binding capacity at high flowrates, thereby increasing the efficiency of your purification. Check out our previous article on the impact of mRNA pore size on binding capacity here.
If you are interested in trying out our Purexa™ OdT products, please feel free to contact us or +1(864) 455-1457